LTFS
SCMP

Ladenburg Thalmann Financial Services’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,186
Closed -$39K – 5337
2017
Q4 		$39K Buy
2,186
+52
+2% +$640 ﹤0.01% 3402
2017
Q3 		$25K Sell
2,134
-181
-8% -$2.03K ﹤0.01% 3570
2017
Q2 		$24K Buy
2,315
+89
+4% +$907 ﹤0.01% 3518
2017
Q1 		$24K Buy
2,226
+616
+38% +$7.15K ﹤0.01% 3452
2016
Q4 		$21K Buy
+1,610
New +$22.5K ﹤0.01% 3466
2016
Q3 		– Sell
-100
Closed -$1K – 4960
2016
Q2 		$1K Buy
100
+98
+4,900% +$1.1K ﹤0.01% 4684
2016
Q1 		$0 Hold
2
– – ﹤0.01% 4919
2015
Q4 		$0 Hold
2
– – ﹤0.01% 4870
2015
Q3 		$0 Sell
2
-698
-100% -$16K ﹤0.01% 4838
2015
Q2 		$12K Buy
+700
New +$12.1K ﹤0.01% 3592

Other funds holding SCMP

GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AIM
Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

Ladenburg Thalmann Financial Services's SCMP Position: Q1 2018 in Review

Ladenburg Thalmann Financial Services sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 2,186 shares — an estimated $39K sold.

Ladenburg Thalmann Financial Services first reported a position in SCMP in Q2 2015 and held it in 10 quarters. The position peaked at $39K in Q4 2017. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.

  • Ladenburg Thalmann Financial Services reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Ladenburg Thalmann Financial Services sold 2,186 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $39K.
  • Ladenburg Thalmann Financial Services first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2015 and held it in 10 quarters.
  • Ladenburg Thalmann Financial Services's Sucampo Pharmaceuticals, Inc. position peaked at $39K in Q4 2017.
  • 3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q1 2018, filed 15 May 2018.